Posted by Michael Wonder on 11 Sep 2018
Bertilimumab granted fast track designation for the treatment of bullous pemphigoid
11 September 2018 - Company to provide corporate update during conference call with live audio webcast on Thursday 13 September at 8:30 am EDT.
Immune Pharmaceuticals announced today that the U.S. FDA has granted fast track designation to bertilimumab for the treatment of bullous pemphigoid.
